Wednesday, June 10, 2026
πŸ‡ΊπŸ‡Έ FDA

pharma Β· Gout Β· Asthma

Sunshine Guojian Pharmaceutical

Sunshine Guojian Pharmaceutical (Shanghai) Co.,

Sunshine Guojian Pharmaceutical drug portfolio β€” 80 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

FORT LAUDERDALE, FL, CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
FORT LAUDERDALE, FL, CN
Programs
165
Drugs
80
Patents
121
All projects Drug pipeline Patents News & analysis
Intelligence Β· Drug Pipeline

Sunshine Guojian Pharmaceutical pipeline

Portfolio lens on 80 drugs and development assets β€” regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Sunshine Guojian Pharmaceutical drug portfolio β€” 80 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

80 compounds

  1. 601 1.25mg

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  2. 626

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  3. [14c]absk011

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  4. alcohol

    US regulatory status: approved.

  6. anti-

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  7. antibody

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  8. aspart

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  9. brivaracetam

    Nervous system (N03)

    US regulatory status: approved. Molecular target: Synaptic vesicle glycoprotein 2A.

    Target
    Synaptic vesicle glycoprotein 2A
    Mechanism
    Synaptic vesicle glycoprotein 2A modulator

  10. capsule

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  11. capsules

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  12. carfilzomib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: 26S proteasome.

    Target
    26S proteasome
    Mechanism
    26S proteosome inhibitor

  13. carisoprodol

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  14. ceftolozane

    Antiinfectives for systemic use (J01)

    Antiinfectives for systemic use (J01) compound in Sunshine Guojian Pharmaceutical's portfolio.

  15. chemotherapy

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  16. chloride

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  17. chlorpheniramine polistirex

    US regulatory status: approved. Molecular target: Histamine H1 receptor.

    Target
    Histamine H1 receptor
    Mechanism
    Histamine H1 receptor antagonist

  18. clascoterone

    Dermatologicals (D10)

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  19. colchicine

    Musculo-skeletal system (M04)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  20. dose

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  21. doxorubicin

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Sunshine Guojian Pharmaceutical's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.

    Mechanism
    DNA topoisomerase II alpha inhibitor

  22. duloxetine hydrochloride

    US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.

    Target
    Sodium-dependent noradrenaline transporter
    Mechanism
    Norepinephrine transporter inhibitor

  23. erythropoietin

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  24. estropipate

    US regulatory status: approved. Molecular target: Estrogen receptor.

    Target
    Estrogen receptor
    Mechanism
    Estrogen receptor alpha agonist

  25. etanercept

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  26. experimental

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  27. formulation

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  28. gls4

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  29. group

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  30. hec110114

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  31. hec74647

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  32. hema-

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  33. hexachlorophene

    US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.

    Target
    Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
    Mechanism
    Bacterial enoyl-[acyl-carrier-protein] reductase inhibitor

  34. hexocyclium methylsulfate

    US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.

    Target
    Muscarinic acetylcholine receptor M1
    Mechanism
    Muscarinic acetylcholine receptor M1 antagonist

  35. human heterologous liver cells

    Alimentary tract and metabolism (A16)

    Alimentary tract and metabolism (A16) compound in Sunshine Guojian Pharmaceutical's portfolio.

  36. hydrocodone bitartrate

    US regulatory status: approved. Molecular target: Opioid receptors; mu/kappa/delta.

    Target
    Opioid receptors; mu/kappa/delta
    Mechanism
    Opioid receptors; mu/kappa/delta agonist

  39. injection

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  40. insulin

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  41. insulin aspart

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  42. insulin degludec

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist

  44. interleukin-

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  45. ketorolac tromethamine

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  46. kn046

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records. Molecular target: Cytotoxic T-lymphocyte protein 4.

    Target
    Cytotoxic T-lymphocyte protein 4
    Mechanism
    Cytotoxic T-lymphocyte protein 4 inhibitor

  47. lacosamide

    Nervous system (N03)

    US regulatory status: approved. Molecular target: Sodium channel alpha subunit.

    Target
    Sodium channel alpha subunit
    Mechanism
    Sodium channel alpha subunit blocker

  48. larotinib

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  49. levodopa + carbidopa

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  50. liraglutide

    Alimentary tract and metabolism (A10)

    US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.

    Target
    Glucagon-like peptide 1 receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist

  52. maintenance

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  53. malignant

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  54. metoprolol succinate

    US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.

    Target
    Beta-1 adrenergic receptor
    Mechanism
    Beta-1 adrenergic receptor antagonist

  55. miconazole nitrate

    US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.

    Target
    Lanosterol 14-alpha demethylase
    Mechanism
    Cytochrome P450 51 inhibitor

  56. midazolam

    Nervous system (N05)

    US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel positive allosteric modulator

  57. minoxidil

    US regulatory status: approved. Molecular target: Sulfonylurea receptor 2, Kir6.2.

    Target
    Sulfonylurea receptor 2, Kir6.2
    Mechanism
    Sulfonylurea receptor 2, Kir6.2 opener

  58. mirabegron

    Genito-urinary system and sex hormones (G04)

    US regulatory status: approved. Molecular target: Beta-3 adrenergic receptor.

    Target
    Beta-3 adrenergic receptor
    Mechanism
    Beta-3 adrenergic receptor agonist

  59. monoclonal

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  60. moxifloxacin hydrochloride

    US regulatory status: approved. Molecular target: Bacterial DNA gyrase.

    Target
    Bacterial DNA gyrase
    Mechanism
    Bacterial DNA gyrase inhibitor

  61. nalfurafine hydrochloride

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records. Molecular target: Kappa-type opioid receptor.

    Target
    Kappa-type opioid receptor
    Mechanism
    Kappa opioid receptor agonist

  62. pimozide

    US regulatory status: approved. Molecular target: Dopamine receptor.

    Target
    Dopamine receptor
    Mechanism
    Dopamine receptor antagonist

  63. placebo

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  64. postoperative

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  65. programmed

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  66. recombinant

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  67. stro-

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  68. sulforaphane

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  69. syrup

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  70. tablet

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  71. tablets

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  76. tenofovir alafenamide

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: Human immunodeficiency virus type 1 reverse transcriptase.

    Target
    Human immunodeficiency virus type 1 reverse transcriptase
    Mechanism
    Human immunodeficiency virus type 1 reverse transcriptase inhibitor

  77. therapy

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  78. topiramate

    US regulatory status: approved. Molecular target: Carbonic anhydrase 2.

    Target
    Carbonic anhydrase 2
    Mechanism
    GABA-A receptor; anion channel positive modulator

  79. treatment

    Development asset linked to Sunshine Guojian Pharmaceutical in public FDA and regional records.

  80. xenon xe-133

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.